Montpellier (France), September 17, 2013 – Amatsigroup, an independent services company in the human and veterinary drug development sector, announces the merger of the companies within its perimeter, Avogadro, Amatsi, DBI and Avepharm.
This operation, which has been prepared in the last months, will allow Amatsigroup to secure its position as a significant player in the field of pharmaceutical development dedicated to pharmaceutical and biotechnology companies.
Amatsigroup offers its clients a wide range of services covering four complementary strategic activities:
- Bioservices: in-life studies and preclinical and clinical bioanalysis
- Pharmaceutical analysis solutions: analytical method development and validation, stability studies, quality control of raw materials and finished products
- Formulation development and manufacturing: formulation development, production of sterile and non-sterile pilot batches
- Clinical trial material logistics: GMP storage, secondary packaging, labelling, QP release services, international distribution
The merger came into effect on August 1st, 2013.
Alain Sainsot, the CEO of Amatsigroup, stated:
“This legal merger represents an important milestone for Amatsigroup, paving the way for the creation of a united group endowed with a sense of common identity, making our offer of global services more comprehensible throughout the pharmaceutical development value chain. Moreover, it marks a fundamental stage in the development of our group and allows us to contemplate a potential international growth operation in the coming months. Today, all our teams are committed to Amatsigroup’s ambition to become a leading European player in the high-potential pharmaceutical development sector.”
About Amatsigroup
Amatsigroup, as a CDMO (Contract Development and Manufacturing Organisation), provides services throughout both preclinical and clinical phases. With more than 200 highly-qualified staff and a diversified portfolio of 600 clients, Amatsigroup is poised to become the leading French company in its sector.
Amatsigroup generates annual sales of 23 million euros and contributes, every year, to the development and registration of more than 30 pharmaceutical products for its clients. The Group operates from facilities based in the South of France and a US commercial office in Cambridge, Massachusetts.
For further information, please visit our website www.amatsigroup.com.
Help employers find you! Check out all the jobs and post your resume.
